Differential effects of antiretroviral drug toxicity in male versus female children who are HIV-exposed but uninfected.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
14
10
2020
medline:
3
3
2021
entrez:
13
10
2020
Statut:
ppublish
Résumé
: In recent years, widespread use of antiretroviral therapy (ART) during pregnancy has been increasingly effective in reducing risk of vertical transmission of HIV, with over 80% of pregnant women living with HIV now accessing ART, and a 41% reduction in new infections in children between 2010 and 2018. Despite these strides, the developmental toxicity of widely administered antiretroviral drugs (ARVs) remains poorly described and existing literature often fails to account for fetal and infant sex as a variable. Recent reports have identified associations between in-utero exposure to commonly used antiretroviral regimens and alteration in neurodevelopment, growth, and metabolism amongst children who are HIV-exposed but uninfected, with findings of sex differences in the prevalence and severity of ARV toxicity. These differences are potentially explained by variable exposure to ARV drugs in utero or exacerbation of existing sex-linked risk factors. Fetal ARV exposure is mediated by placental and fetal drug transporters and metabolic enzymes, which may contribute to the manifestation of sex differences. Existing evidence of sex differences in ARV toxicity in fetal development is concerning, and demands further research to guide optimal treatment options for maternal health and prevention of vertical HIV transmission.
Identifiants
pubmed: 33048885
doi: 10.1097/QAD.0000000000002707
pii: 00002030-202101010-00001
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-14Subventions
Organisme : CIHR
Pays : Canada
Références
UNAIDS. Global HIV & AIDS statistics — 2019 fact sheet. 2019.
World Health Organization. Update of Recommendations on first- and second-line antiretroviral regimens; 2019.
Kellerman SE, Ahmed S, Feeley-summerl T, Jay J, Maria H, Koumans E, et al. Beyond PMTCT: keeping exposed and positive children healthy and alive . AIDS 2013; 27:1–15.
Bailey H. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes . AIDS 2019; 33:295–304.
Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis . J Acquir Immune Defic Syndr 2017; 76:1–12.
Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, et al. Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana . J Acquir Immune Defic Syndr 2016; 4:428–436.
Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global population of children who are HIV-exposed and uninfected, 2000-18: a modelling study . Lancet Glob Heal 2020; 8:e67–e75.
World Health Organization. Preventing HIV during pregnancy and breastfeeding in the context of PREP. 2017.
Pintye J, Davey DLJ, Wagner AD, John-Stewart G, Baggaley R, Bekker LG, et al. Defining gaps in preexposure prophylaxis delivery for pregnant and postpartum women in high-burden settings using an implementation science framework . Lancet HIV 2020; 7:e582–e592.
Eckard AR, Kirk SE, Hagood NL. Contemporary issues in pregnancy (and offspring) in the current HIV era . Curr HIV/AIDS Rep 2019; 16:492–500.
Wedderburn CJ, Evans C, Yeung S, Gibb DM, Donald KA, Prendergast AJ. Growth and neurodevelopment of HIV-exposed uninfected children: a conceptual framework . Curr HIV/AIDS Rep 2019; 16:501–513.
Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR III. The PHACS SMARTT study: assessment of the safety of in utero exposure to antiretroviral drugs . Front Immunol 2016; 7:199.
Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention . N Engl J Med 2016; 375:1726–1737.
Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection . Pharmacol Res 2008; 58:173–182.
Brennan AT, Bonawitz R, Gill CJ, Thea DM, Kleinman M, Useem J, et al. A meta-analysis assessing all-cause mortality in HIVexposed uninfected compared with HIV-unexposed uninfected infants and children . AIDS 2016; 30:2351–2360.
Arikawa S, Rollins N, Newell ML, Becquet R. Mortality risk and associated factors in HIV-exposed, uninfected children . Trop Med Int Heal 2016; 21:720–734.
Yeganeh N, Watts DH, Xu J, Kerin T, Joao EC, Pilotto JH, et al. Infectious morbidity, mortality and nutrition in HIV-exposed, uninfected, formula-fed infants . Pediatr Infect Dis J 2018; 37:1271–1278.
Le Roux DM, Nicol MP, Myer L, Vanker A, Stadler JAM, Von Delft E, et al. Lower respiratory tract infections in children in a well vaccinated South African Birth Cohort: spectrum of disease and risk factors . Clin Infect Dis 2019; 69:1588–1596.
Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of infectious morbidity in HIV-exposed uninfected infants and children . Front Immunol 2016; 7:164.
Ramokolo V, Goga AE, Lombard C, Doherty T, Jackson DJ, Engebretsen IM. In utero ART exposure and birth and early growth outcomes among HIV-exposed uninfected infants attending immunization services: results from National PMTCT Surveillance, South Africa . Open Forum Infect Dis 2017; 4:ofx187.
Hoffman RM, Brummel SS, Britto P, Pilotto JH, Masheto G, Aurpibul L, et al. PROMISE (Promoting Maternal and Infant Safety Everywhere) 1077HS Team. Adverse pregnancy outcomes among women who conceive on antiretroviral therapy . Clin Infect Dis 2019; 68:273–279.
Slogrove AL, Powis KM. Fetal origins of postnatal growth faltering in HIV-exposed uninfected children . Lancet Child Adolesc Heal 2019; 3:201–203.
McHenry MS, Balogun KA, McDonald BC, Vreeman RC, Whipple EC, Serghides L. In utero exposure to HIV and/or antiretroviral therapy: a systematic review of preclinical and clinical evidence of cognitive outcomes . J Int AIDS Soc 2019; 22:e2527524.
Sirois PA, Huo Y, Williams PL, Malee K, Garvie PA, Kammerer B, et al. Pediatric HIVAIDS Cohort Study. Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants . Pediatr Infect Dis J 2013; 32:648–655.
Smith ML, Puka K, Sehra R, Read SE, Bitnun A. Longitudinal development of cognitive, visuomotor and adaptive behavior skills in HIV uninfected children, aged 3-5 years of age, exposed pre and perinatally to antiretroviral medications . AIDS Care Psychol Socio-Medical Asp AIDS/HIV 2017; 29:1302–1308.
Reliquet V, Brunet-Cartier C, Launay E, Raffi F. Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants . Transl Pediatr 2017; 6:27–31.
Snijdewind IJM, Smit C, Godfried MH, Bakker R, Nellen JFJB, Jaddoe VWV, et al. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age . PLoS One 2018; 13:e0191389.
Desmonde S, Goetghebuer T, Thorne C, Leroy V. Health and survival of HIV perinatally exposed but uninfected children born to HIV-infected mothers . Curr Opin HIV AIDS 2016; 11:465–476.
Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The immune system of HIV-exposed uninfected infants . Front Immunol 2016; 7:383.
le Roux SM, Abrams EJ, Nguyen K, Myer L. Clinical outcomes of HIV-exposed, HIV-uninfected children in sub-Saharan Africa . Trop Med Int Heal 2016; 21:829–845.
Ejigu Y, Magnus JH, Sundby J, Magnus MC. Differences in growth of HIV-exposed uninfected infants in Ethiopia according to timing of in-utero antiretroviral therapy exposure . Pediatr Infect Dis J 2020; 39:730–736.
Seidel V, Weizsäcker K, Henrich W, Rancourt RC, Bührer C, Krüger R, et al. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants . Eur J Pediatr 2020; 179:99–109.
Aizire J, Sikorskii A, Ogwang LW, Kawalazira R, Mutebe A, Familiar-Lopez I, et al. Decreased growth among antiretroviral drug and HIV exposed uninfected versus unexposed children in Malawi and Uganda . AIDS 2020; 34:215–225.
Powis KM, Smeaton L, Hughes MD, Tumbare EA, Souda S, Jao J, et al. In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana . AIDS 2016; 30:211–220.
Hofer CB, Keiser O, Zwahlen M, Lustosa CS, Frota ACC, De Oliveira RH, et al. In utero exposure to antiretroviral drugs: effect on birth weight and growth among HIV-exposed uninfected children in Brazil . Pediatr Infect Dis J 2016; 35:71–77.
Crowell CS, Williams PL, Yildirim C, Van Dyke RB, Smith R, Chadwick EG, et al. Pediatric HIV/AIDS Cohort Study. Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected . AIDS 2020; 34:1377–1387.
Williams PL, Yildirim C, Chadwick EG, Van Dyke RB, Smith R, Correia KF, et al. Surveillance Monitoring for ART Toxicities (SMARTT) study of the Pediatric HIV/AIDS Cohort Study. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study . Lancet HIV 2020; 7:e49–e58.
Cassidy AR, Williams PL, Leidner J, Mayondi G, Ajibola G, Makhema J, et al. In utero efavirenz exposure and neurodevelopmental outcomes in HIV-exposed uninfected children in Botswana . Pediatr Infect Dis J 2019; 38:828–834.
Zash R, Holmes L, Diseko M, Jacobson DL, Brummel S, Mayondi G, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana . N Engl J Med 2019; 381:827–840.
Wedderburn CJ, Yeung S, Rehman AM, Stadler JAM, Nhapi RT, Barnett W, et al. Neurodevelopment of HIV-exposed uninfected children in South Africa: outcomes from an observational birth cohort study . Lancet Child Adolesc Health 2019; 3:803–813.
Boivin MJ, Maliwichi-Senganimalunje L, Ogwang LW, Kawalazira R, Sikorskii A, Familiar-Lopez I, et al. Neurodevelopmental effects of ante-partum and postpartum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study . Lancet HIV 2019; 6:e518–e530.
Piske M, Budd MA, Qiu AQ, Maan EJ, Sauvé LJ, Forbes JC, et al. CIHR Team Grant on Cellular Aging and HIV Comorbidities in Women and Children (CARMA). Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children . AIDS 2018; 32:2583–2592.
Chaudhury S, Williams PL, Mayondi GK, Leidner J, Holding P, Tepper V, et al. Neurodevelopment of HIV-exposed and HIV-unexposed uninfected children at 24 months . Pediatrics 2017; 140:e20170988.
Caniglia EC, Patel K, Huo Y, Williams PL, Kapetanovic S, Rich KC, et al. Pediatric HIVAIDS Cohort Study. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study . AIDS 2016; 30:1267–1278.
Himes SK, Huo Y, Siberry GK, Williams PL, Rice ML, Sirois PA, et al. Pediatric HIVAIDS Cohort Study. Meconium atazanavir concentrations and early language outcomes in HIV-exposed uninfected infants with prenatal atazanavir exposure . J Acquir Immune Defic Syndr 2015; 69:178–186.
Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM. PACTG 219C Team. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants . Pediatrics 2010; 125:e250–e260.
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception . N Engl J Med 2018; 379:979–981.
Rice ML, Zeldow B, Siberry GK, Purswani M, Malee K, Hoffman HJ, et al. Pediatric HIVAIDS Cohort Study (PHACS). Evaluation of risk for late language emergence after in utero antiretroviral drug exposure in HIV-exposed uninfected infants . Pediatr Infect Dis J 2013; 32:e406–e413.
Spaulding AB, Yu Q, Civitello L, Mussi-Pinhata MM, Pinto J, Gomes IM, et al. Neurologic outcomes in HIV-exposed/uninfected infants exposed to antiretroviral drugs during pregnancy in Latin America and the Caribbean . AIDS Res Hum Retroviruses 2016; 32:349–356.
Kacanek D, Williams PL, Mayondi G, Holding P, Leidner J, Moabi K, et al. Pediatric neurodevelopmental functioning after in utero exposure to triple-NRTI vs. dual-NRTI + PI ART in a randomized trial, Botswana . J Acquir Immune Defic Syndr 2018; 79:e93–e100.
Blanche S, Tylleskär T, Peries M, Kankasa C, Engebretsen I, Meda N, et al. Growth in HIV-1-exposed but uninfected infants treated with lopinavir–ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial . Lancet HIV 2019; 6:e307–e314.
Sebikari D, Farhad M, Fenton T, Owor M, Stringer JSA, Qin M, et al. Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial . J Acquir Immune Defic Syndr 2019; 81:521–532.
Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction . J Infect Dis 2015; 211:10–18.
Papp E, Balogun K, Banko N, Mohammadi H, Loutfy M, Yudin MH, et al. Low prolactin and high 20-(-hydroxysteroid dehydrogenase levels contribute to lower progesterone levels in hiv-infected pregnant women exposed to protease inhibitor-based combination antiretroviral therapy . J Infect Dis 2016; 213:1532–1540.
Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in botswana . J Infect Dis 2012; 206:1695–1705.
Powis KM, Shapiro RL. Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle? . J Infect Dis 2015; 211:4–7.
Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188 . J Acquir Immune Defic Syndr 2010; 55:473–482.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. 2016.
Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences . Gend Med 2007; 4:106–119.
Onyango-Makumbi C, Owora AH, Mwiru RS, Mwatha A, Young AM, Moodley D, et al. Extended prophylaxis with nevirapine does not affect growth in HIV-exposed infants . J Acquir Immune Defic Syndr 2019; 82:377–385.
Lane CE, Bobrow EA, Ndatimana D, Ndayisaba GF, Adair LS. Determinants of growth in HIV-exposed and HIV-uninfected infants in the Kabeho Study . Matern Child Nutr 2019; 15:e12776.
Morden E, Technau KG, Giddy J, Maxwell N, Keiser O, Davies MA. Growth of HIV-exposed uninfected infants in the first 6 months of life in South Africa: the IeDEA-SA Collaboration . PLoS One 2016; 11:e0151762.
Powis KM, Smeaton L, Ogwu A, Lockman S, Dryden-Peterson S, Van Widenfelt E, et al. Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana . J Acquir Immune Defic Syndr 2011; 56:131–138.
Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study) . J Am Coll Cardiol 2011; 57:76–85.
Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia . J Clin Oncol 2005; 23:2629–2636.
Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer . N Engl J Med 1995; 332:1738–1744.
Chan SSL, Santos JH, Meyer JN, Mandavilli BS, Cook DL, McCash CL, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination . Environ Mol Mutagen 2007; 48:190–200.
Condo JU, Gage A, Mock N, Rice J, Greiner T. Sex differences in nutritional status of HIV-exposed children in Rwanda: a longitudinal study . Trop Med Int Heal 2015; 20:17–23.
Parker ME, Tembo M, Adair L, Chasela C, Piwoz EG, Jamieson DJ, et al. BAN Study Team. The health of HIV-exposed children after early weaning . Matern Child Nutr 2013; 9:217–232.
Widen E, Bentley ME, Kayira D, Chasela CS, Jamieson DJ, Tembo M, et al. BAN Study team. Maternal weight loss during exclusive breastfeeding is associated with reduced weight and length gain in daughters of HIV-infected Malawian women . J Nutr 2013; 143:1168–1175.
Taha T, Nour S, Li Q, Kumwenda N, Kafulafula G, Nkhoma C, Broadhead R. The effect of human immunodeficiency virus and breastfeeding on the nutritional Status of African children . Pediatr Infect Dis J 2010; 29:514–518.
le Roux SM, Abrams EJ, Donald KA, Brittain K, Phillips TK, Nguyen KK, et al. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study . Lancet Child Adolesc Heal 2019; 3:234–244.
Boivin MJ, Barlow-Mosha L, Chernoff MC, Laughton B, Zimmer B, Joyce C, et al. IMPAACT P1104s Study Team. Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial . AIDS 2018; 32:189–204.
Terasaki LS, Gomez J, Schwarz JM. An examination of sex differences in the effects of early-life opiate and alcohol exposure . Philos Trans R Soc B Biol Sci 2016; 371:20150123.
McCarthy MM, Arnold AP. Reframing sexual differentiation of the brain . Nat Neurosci 2011; 14:677–683.
DiPietro JA, Voegtline KM. The gestational foundation of sex differences in development and vulnerability . Neuroscience 2017; 342:4–20.
May T, Adesina I, McGillivray J, Rinehart NJ. Sex differences in neurodevelopmental disorders . Curr Opin Neurol 2019; 32:622–626.
Rosenfeld CS. Sex-specific placental responses in fetal development . Endocrinology 2015; 156:3422–3434.
Clifton VL. Review: sex and the human placenta: mediating differential strategies of fetal growth and survival . Placenta 2010; 31: (Suppl A): S33–S39.
Alam C, Whyte-Allman S-K, Omeragic A, Bendayan R. Role and modulation of drug transporters in HIV-1 therapy . Adv Drug Deliv Rev 2016; 103:121–143.
Kis O, Robillard K, Chan GNY, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters . Trends Pharmacol Sci 2010; 31:22–35.
Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding . Pharmacogenomics 2012; 13:1501–1522.
Pfeifer C, Bunders MJ. Maternal HIV infection alters the immune balance in the mother and fetus: implications for pregnancy outcome and infant health . Curr Opin HIV AIDS 2016; 11:138–145.
Howerton CL, Morgan CP, Fischer DB, Bale TL. O-GlcNAc transferase (OGT) as a placental biomarker of maternal stress and reprogramming of CNS gene transcription in development . Proc Natl Acad Sci U S A 2013; 110:5169–5174.
Nugent BM, O’Donnell CM, Epperson CN, Bale TL. Placental H3K27me3 establishes female resilience to prenatal insults . Nat Commun 2018; 9:2555.
Howerton CL, Bale TL. Targeted placental deletion of OGT recapitulates the prenatal stress phenotype including hypothalamic mitochondrial dysfunction . Proc Natl Acad Sci U S A 2014; 111:9639–9644.
Poirier MC, Divi RL, Al-Harthi L, Olivero OA, Nguyen V, Walker B, et al. Women and Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers . J Acquir Immune Defic Syndr 2003; 33:175–183.
Poirier MC, Gibbons AT, Rugeles MT, Andre-Schmutz I, Blanche S. Fetal consequences of maternal antiretroviral nucleoside reverse transcriptase inhibitor use in human and nonhuman primate pregnancy . Curr Opin Pediatr 2015; 27:233–239.
Arnold AP, Chen X, Itoh Y. What a difference an X or Y makes: sex chromosomes, gene dose, and epigenetics in sexual differentiation . Handb Exp Pharmacol 2012; 214:67–88.
Buckberry S, Bianco-Miotto T, Bent SJ, Dekker GA, Roberts CT. Integrative transcriptome metaanalysis reveals widespread sex-biased gene expression at the human fetal-maternal interface . Mol Hum Reprod 2014; 20:810–819.
Walker N, Filis P, Soffientini U, Bellingham M, O'Shaughnessy PJ, Fowler PA. Placental transporter localization and expression in the human: the importance of species, sex, and gestational age difference . Biol Reprod 2017; 96:733–742.
Yasuda S, Itagaki S, Hirano T, Iseki K. Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo . J Pharm Pharm Sci 2006; 9:133–139.
Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function . Reprod Toxicol 2006; 22:400–410.
Vore M, Leggas M. Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression . Mol Pharmacol 2008; 73:613–615.
Kis O, Zastre JA, Hoque MT, Walmsley SL, Bendayan R. Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions . Pharm Res 2013; 30:1050–1064.
Cannon C, Daood MJ, O’Day TL, Watchko JF. Sex-specific regional brain bilirubin content in hyperbilirubinemic Gunn rat pups . Biol Neonate 2006; 90:40–45.
Tioseco JA, Aly H, Milner J, Patel K, El-Mohandes AAE. Does gender affect neonatal hyperbilirubinemia in low-birth-weight infants? . Pediatr Crit Care Med 2005; 6:171–174.
Mandelbrot L, Mazy F, Floch-Tudal C, Meier F, Azria E, Crenn-Hebert C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia . Eur J Obstet Gynecol Reprod Biol 2011; 157:18–21.
Ip S, Chung M, Kulig J, O’Brien R, Sege R, Glicken S, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia . Pediatrics 2004; 114:e140–e153.
Babu TA, Bhat BV, Joseph NM. Neurobehavior of term neonates with neonatal hyperbilirubinemia . J Pediatr Neurosci 2013; 8:11–14.
Fujiwara R, Haag M, Schaeffeler E, Nies AT, Zanger UM, Schwab M. Systemic regulation of bilirubin homeostasis: potential benefits of hyperbilirubinemia . Hepatology 2018; 67:1609–1619.
Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D. Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1 ∗ 28 allele . Pharmgenomics Pers Med 2017; 10:205–208.
Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Griffith Humphreys W. In vitro inhibition of udp glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation . Drug Metab Dispos 2005; 33:1729–1739.
Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1 . Xenobiotica 2010; 40:163–176.
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, et al. International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Raltegravir pharmacokinetics in neonates following maternal dosing . J Acquir Immune Defic Syndr 2014; 67:310–315.
Burger DM. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies . Expert Opin Drug Metab Toxicol 2010; 6:1151–1160.
Li Y, Wu T, Chen L, Zhu Y. Associations between G6PD, OATP1B1 and BLVRA variants and susceptibility to neonatal hyperbilirubinaemia in a Chinese Han population . J Paediatr Child Health 2019; 55:1077–1083.
Chiddarwar AS, D'Silva SZ, Colah RB, Ghosh K, Mukherjee MB. Genetic variations in bilirubin metabolism genes and their association with unconjugated hyperbilirubinemia in adults . Ann Hum Genet 2017; 81:11–19.
Min J, Jie L, Caiyun Y, Ying L, Xuefang Y. Gene mutation in neonatal jaundice – mutations in UGT1A1 and OATP2 genes . Indian J Pediatr 2016; 83:723–725.
Büyükkale G, Turker G, Kasap M, Akpnar G, Arsoy E, Günlemez A, et al. Neonatal hyperbilirubinemia and organic anion transporting polypeptide-2 gene mutations . Am J Perinatol 2011; 28:619–626.
Yu Z, Zhu K, Wang L, Liu Y, Sun J. Association of neonatal hyperbilirubinemia with UGT1A1 gene polymorphisms: a meta-analysis . Med Sci Monit 2015; 21:3104–3114.
Morissette P, Albert C, Busque S, St-Louis G, Vinet B. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil . Ther Drug Monit 2001; 23:520–525.
Shiratani H, Katoh M, Nakajima M, Yokoi T. Species differences in UDP-glucuronosyltransferase activities in mice and rats . Drug Metab Dispos 2008; 36:1745–1752.
Dellinger RW, Garcia AMG, Meyskens FL. Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences . Drug Metab Pharmacokinet 2014; 29:112–119.
Yang L, Li Y. Sex differences in the expression of drug-metabolizing and transporter genes in human liver . J Drug Metab Toxicol 2012; 3:1000119.
Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro . Basic Clin Pharmacol Toxicol 2006; 98:79–85.
Gong Y, Haque S, Chowdhury P, Cory TJ, Kodidela S, Yallapu MM, et al. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment . Expert Opin Drug Metab Toxicol 2019; 15:417–427.
Kile DA, Mawhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir . AIDS Res Hum Retroviruses 2012; 28:1227–1234.
Van Waterschoot RAB, Ter Heine R, Wagenaar E, Van Der Kruijssen CMM, Rooswinkel RW, Huitema ADR, et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir . Br J Pharmacol 2010; 160:1224–1233.
Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans . Expert Opin Drug Metab Toxicol 2008; 4:413–424.
Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men . J Clin Pharmacol 2011; 51:1665–1673.
Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, et al. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202 . J Antimicrob Chemother 2014; 69:3300–3310.
Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein . J Pharmacol Exp Ther 2006; 316:1202–1209.
Leeder JS, Gaedigk R, Marcucci KA, Gaedigk A, Vyhlidal CA, Schindel BP, Pearce RE. Variability of CYP3A7 expression in human fetal liver . J Pharmacol Exp Ther 2005; 314:626–635.
Williams AJ, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7 . Drug Metab Dispos 2002; 30:883–891.
Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis . AIDS 2006; 20:675–684.
Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy . Pharmacology 2008; 82:83–88.
Hernàndez S, Morén C, López M, Coll O, Cardellach F, Gratacós E, et al. Perinatal outcomes, mitochondrial toxicity and apoptosis in HIV-treated pregnant women and in-utero-exposed newborn . AIDS 2012; 26:419–428.
Ross AC, Leong T, Avery A, Castillo-Duran M, Bonilla H, Lebrecht D, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress . HIV Med 2012; 13:98–106.
Brogly SB, Dimauro S, Van Dyke RB, Williams PL, Naini A, Libutti DE, et al. Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children . AIDS Res Hum Retroviruses 2011; 27:777–783.
Budd MA, Calli K, Samson L, Bowes J, Hsieh AYY, Forbes JC, et al. Blood mitochondrial DNA content in HIV-exposed uninfected children with autism spectrum disorder . Viruses 2018; 10:77.
Jao J, Powis KM, Kirmse B, Yu C, Epie F, Nshom E, et al. Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon . AIDS 2017; 31:2475–2481.
Schoeman JC, Moutloatse GP, Harms AC, Vreeken RJ, Scherpbier HJ, Leeuwen L, Van, et al. Fetal metabolic stress disrupts immune homeostasis and induces proinflammatory responses in human immunodeficiency virus type 1 and combination antiretroviral therapy-exposed infants . J Infect Dis 2017; 216:436–446.
Blanche S, Tardieu M, Rustin P, Slama A, Barret BE, Firtion G, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues . Lancet 1999; 354:1084–1089.
Noguera-Julian A, Morén C, Rovira N, Garrabou G, Catalán M, Sánchez E, et al. Decreased mitochondrial function among healthy infants exposed to antiretrovirals during gestation, delivery and the neonatal period . Pediatr Infect Dis J 2015; 34:1349–1354.
Lipshultz SE, Sasaki N, Thompson B, Eidem BW, Cheng I, Colan SD, et al. Left ventricular diastolic dysfunction in HIV-uninfected infants exposed in utero to antiretroviral therapy . AIDS 2020; 34:529–537.
García-Otero L, López M, Guitart-Mampel M, Morén C, Goncé A, Esteve C, et al. Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment . PLoS One 2019; 14:e0213279.
Sibiude J, Le Chenadec J, Bonnet D, Tubiana R, Faye A, Dollfus C, et al. French National Agency for Research on AIDS and Viral Hepatitis French Perinatal Cohort/Protease Inhibitor Monotherapy Evaluation Trial. In utero exposure to zidovudine and heart anomalies in the ANRS French Perinatal Cohort and the Nested PRIMEVA Randomized Trial . Clin Infect Dis 2015; 61:270–280.
Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals . AIDS 2003; 17:2159–2168.
Miller SR, Hau RK, Jilek JL, Morales MN, Wright SH, Cherrington NJ. Nucleoside reverse transcriptase inhibitor interaction with human equilibrative nucleoside transporters 1 and 2 . Drug Metab Dispos 2020; 48:603–612.
Koczor CA, Torres RA, Lewis W. The role of transporters in the toxicity of nucleoside and nucleotide analogs . Expert Opin Drug Metab Toxicol 2012; 8:665–676.
Leung GPH, Tse CM. The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity . Expert Opin Drug Metab Toxicol 2007; 3:705–718.
Zeng Q, Bai M, Li C, Lu S, Ma Z, Zhao Y, et al. Multiple drug transporters contribute to the placental transfer of emtricitabine . Antimicrob Agents Chemother 2019; 63:199–218.
Cerveny L, Ptackova Z, Ceckova M, Karahoda R, Karbanova S, Jiraskova L, et al. Equilibrative nucleoside transporter 1 (ENT1, SLC29A1) facilitates transfer of the antiretroviral drug abacavir across the placenta . Drug Metab Dispos 2018; 46:1817–1826.
Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice . Drug Metab Dispos 2004; 32:1455–1461.